Aclaris Therapeutics, Inc. 4

Chief Scientific Officer Roland Wilhelm Kolbeck had 36,375 RSUs in Aclaris Therapeutics, Inc. vest into common stock and 12,385 shares withheld for taxes, resulting in 23,990 shares owned directly.

On August 1, 2026, Aclaris Therapeutics, Inc. Chief Scientific Officer Roland Wilhelm Kolbeck had 36,375 restricted stock units vest and convert into common stock, increasing his direct common stock holdings by 36,375 shares. In connection with this vesting, 12,385 shares of common stock were withheld by the issuer at an implied price of $5.20 per share to cover tax withholding obligations, leaving him with 23,990 shares of common stock directly owned after the net settlement. The RSU award represents routine equity compensation, with each restricted stock unit corresponding to one share of common stock and the underlying award scheduled to vest in four equal installments on the first through fourth anniversaries of August 1, 2025, contingent on his continued service.

Filing Facts

CIK

1557746

Ticker

ACRS

Form

4

Source Type

fda

Accession

0002076327-26-000006

Alert Tier

5